RZLT.US Rezolute Inc

Healthcare Biotechnology USA Stocks
4.01 USD
Close of Nov 17, 2026
1.07 11.17
Market cap
USD 477M
P/E
-
P/B
4.03x
ROE
-86.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is RZLT.US undervalued?

Graham number

The Graham number of Rezolute Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rezolute Inc fundamental analysis

No fundamental analysis for Rezolute Inc yet.

Rezolute Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rezolute Inc

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, In…

Full company profile